Home » Stocks » PRTA

Prothena Corporation PLC (PRTA)

Stock Price: $13.74 USD 0.15 (1.10%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
Market Cap 548.92M
Revenue (ttm) 749,000
Net Income (ttm) -101.98M
Shares Out 39.92M
EPS (ttm) -2.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $13.74
Previous Close $13.59
Change ($) 0.15
Change (%) 1.10%
Day's Open 13.64
Day's Range 13.38 - 13.92
Day's Volume 118,952
52-Week Range 7.54 - 14.40

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

DUBLIN, Ireland, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of inves...

Zacks Investment Research - 1 month ago

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 2 months ago

Prothena (PRTA) misses earnings and sales estimates in the third quarter of 2020.

Zacks Investment Research - 2 months ago

Prothena (PRTA) delivered earnings and revenue surprises of -13.24% and -70.54%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 2 months ago

DUBLIN, Ireland, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of inves...

GlobeNewsWire - 2 months ago

DUBLIN, Ireland, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of inves...

GlobeNewsWire - 2 months ago

DUBLIN, Ireland, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of inves...

Zacks Investment Research - 2 months ago

Prothena (PRTA) and partner Roche (RHHBY) plan to advance prasinezumab into a phase IIb study in patients with early Parkinson's disease.

GlobeNewsWire - 2 months ago

DUBLIN, Ireland, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of inves...

GlobeNewsWire - 3 months ago

DUBLIN, Ireland, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigat...

GlobeNewsWire - 4 months ago

DUBLIN, Ireland, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investi...

GlobeNewsWire - 4 months ago

DUBLIN, Ireland, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), announced that results from the Phase 2 PASADENA study of prasinezumab are being highlighted today...

GlobeNewsWire - 4 months ago

DUBLIN, Ireland, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investi...

Zacks Investment Research - 4 months ago

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 4 months ago

DUBLIN, Ireland, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investi...

Zacks Investment Research - 5 months ago

Prothena (PRTA) delivered earnings and revenue surprises of -3.13% and 11.43%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 5 months ago

DUBLIN, Ireland, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investig...

GlobeNewsWire - 5 months ago

DUBLIN, Ireland, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investig...

GlobeNewsWire - 5 months ago

DUBLIN, Ireland, July 30, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeleine of investi...

Zacks Investment Research - 5 months ago

Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 6 months ago

Prothena (PRTA) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.

Zacks Investment Research - 8 months ago

Prothena (PRTA) delivered earnings and revenue surprises of 1.67% and -37.33%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 8 months ago

DUBLIN, Ireland, April 22, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, announced that today R...

GlobeNewsWire - 9 months ago

DUBLIN, Ireland, March 31, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced that b...

Zacks Investment Research - 10 months ago

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 11 months ago

Prothena (PRTA) reports a narrower-than-expected Q4 loss, while revenues surpass estimates.

Seeking Alpha - 11 months ago

Prothena Corporation (PRTA) CEO Gene Kinney on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

Prothena (PRTA) delivered earnings and revenue surprises of 16.92% and 28.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Prothena (PRTA) stock based on the movements in the options market lately.

GlobeNewsWire - 1 year ago

DUBLIN, Ireland, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, announced today the appointment of Oleg Nodelman to its Boar...

Zacks Investment Research - 1 year ago

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 1 year ago

Prothena (PRTA) posts a narrower Q3 loss while sales surpass estimates.

Zacks Investment Research - 1 year ago

Prothena (PRTA) delivered earnings and revenue surprises of 9.26% and 36.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GuruFocus - 1 year ago

Finding stocks with a negative enterprise value is an excellent way to find deep value

Other stocks mentioned: ACTG, BKEP, HCHC
Zacks Investment Research - 1 year ago

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?

Seeking Alpha - 1 year ago

Shares have fallen by 38% over the past year.

Zacks Investment Research - 1 year ago

Prothena (PRTA) delivered earnings and revenue surprises of 28.57% and -22.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 1 year ago

Prothena's (PRTA) Q1 loss was narrower than expected, while revenues missed expectations.

About PRTA

Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal d... [Read more...]

Industry
Biotechnology
Founded
2012
CEO
Gene Kinney
Employees
51
Stock Exchange
NASDAQ
Ticker Symbol
PRTA
Full Company Profile

Financial Performance

In 2019, Prothena's revenue was $814,000, a decrease of -14.76% compared to the previous year's $955,000. Losses were -$77.68 million, -50.09% less than in 2018.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Prothena stock is "Buy." The 12-month stock price forecast is 19.17, which is an increase of 39.52% from the latest price.

Price Target
$19.17
(39.52% upside)
Analyst Consensus: Buy